Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Serostim Market Size Forecast: How Large Could The Market Become By 2030?
The historic period’s expansion was driven by the accessibility of recombinant somatropin preparations, enhanced handling of HIV-related wasting, broader antiretroviral therapy availability, greater clinical awareness of cachexia, and progress in specialized endocrinology therapies.
The forecast period’s expansion is driven by heightened attention to therapies that enhance quality of life, greater uptake of complementary HIV treatments, the broadening of home-care approaches, increasing need for metabolic support solutions, and progress in sustained-release hormone preparations. Key developments reshaping this timeframe involve the growing adoption of recombinant growth hormone treatments, a stronger focus on managing cachexia, rising demand for interventions aimed at improving body composition, the extension of prolonged hormone therapy initiatives, and better tracking of therapeutic results.
Download A Free Sample Report For Comprehensive Market Insights:
#Serostim Market Growth Factors: Which Forces Are Supporting Market Expansion?
The increasing number of HIV/AIDS cases is anticipated to drive expansion in the serostim market. HIV/AIDS represents a viral condition that compromises immune function and can lead to acquired immunodeficiency syndrome (AIDS) if left untreated. Factors like unprotected sexual activity, inadequate healthcare access, insufficient awareness, and social stigma fuel the rising prevalence of this virus. Serostim aids individuals with HIV/AIDS by facilitating weight gain, boosting lean body mass, and enhancing physical strength, thus mitigating HIV-related wasting symptoms and improving life quality. In October 2024, the UK Health Security Agency, a government body, reported that England had 6,008 new HIV diagnoses in 2023, a 51% surge from the 3,975 cases in 2022. Consequently, the growing incidence of HIV/AIDS is stimulating serostim market growth.
The serostim market is expected to be driven forward by the increasing prevalence of target diseases. These are specific health conditions or illnesses that receive primary focus in treatment, intervention, or research due to their high frequency or severity. Their rising occurrence stems from aging populations, unhealthy lifestyle habits, environmental factors, and improved diagnostic capabilities. Serostim counteracts muscle wasting and loss of lean body mass by activating growth hormone receptors, which boosts protein synthesis and rebuilds muscle and tissue. For example, in March 2024, the US-based Centers for Disease Control and Prevention noted a rise in tuberculosis cases from 8,320 in 2022 to 9,615 in 2023, an increase of 1,295 cases. Hence, the rising prevalence of target diseases is fueling serostim market growth.
The serostim market is expected to be propelled by the rising incidence of chronic diseases. These are persistent medical conditions lasting a year or longer, often requiring continuous care, including ailments like diabetes, heart disease, and asthma. Their increase is linked to sedentary lifestyles, where reduced physical activity leads to weight gain, metabolic issues, and weakened cardiovascular health. Serostim helps manage chronic diseases by improving muscle mass, energy levels, and metabolic stability in patients with muscle wasting, thereby enhancing physical function and aiding in the effective management of long-term health issues. According to the Australian Institute of Health and Welfare (AIHW), a government agency, in July 2024, chronic conditions accounted for 78% of the total fatal burden, representing an increase from prior years. Therefore, the growing incidence of chronic diseases is driving serostim market expansion.
Serostim Market Segmentation And Category Breakdown
The serostim market covered in this report is segmented –
1) By Indication: HIV-Associated Wasting Syndrome, Cachexia
2) By Distribution Channel: Direct Sales, Pharmacies, Wholesalers
3) By End Use: Hospitals, Clinics, Ambulatory Care, Home Care
Serostim Market Competitive Analysis Of Major Industry Participants
Major companies operating in the serostim market are EMD Serono Inc.
Access The Complete Serostim Market Report:
Serostim Market Largest Region By Revenue And Market Share
North America was the largest region in the serostim market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the serostim market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model